Weinstein H J, Lack E E, Cassady J R
Blood. 1984 Aug;64(2):422-6.
Twenty-nine patients with biopsy-proven malignant lymphoma of large-cell "histiocytic" type were treated with the APO protocol (vincristine, adriamycin, and prednisone). Treatment consisted of two years of therapy with a modified adriamycin-containing acute lymphoblastic leukemia regimen with preventive cranial irradiation and regional radiotherapy (for patients with clinically localized lymphoma). The median age was 13 years (range, two to 20 years). Thirteen patients had localized disease (stage I, II), and 16 had disseminated disease (stage III, IV). The median follow-up is four years (range, seven months to nine years), and Kaplan-Meier estimates of overall and relapse-free survival are 83% and 76%, respectively. No recurrences have been observed in primary or bulk sites of lymphoma in the group of children treated with chemotherapy only. We conclude that the APO protocol, which was modeled after an acute lymphoblastic leukemia regimen, combined with regional radiotherapy can produce long-term remissions for children with malignant lymphoma of large cell "histiocytic" type.
29例经活检证实为大细胞“组织细胞”型恶性淋巴瘤的患者接受了APO方案（长春新碱、阿霉素和泼尼松）治疗。治疗采用改良的含阿霉素的急性淋巴细胞白血病方案，为期两年，并进行预防性颅脑照射和局部放疗（针对临床局限性淋巴瘤患者）。中位年龄为13岁（范围为2至20岁）。13例患者为局限性疾病（I期、II期），16例为播散性疾病（III期、IV期）。中位随访时间为4年（范围为7个月至9年），采用Kaplan-Meier法估计的总生存率和无复发生存率分别为83%和76%。仅接受化疗的儿童组中，淋巴瘤的原发部位或肿块部位未观察到复发。我们得出结论，以急性淋巴细胞白血病方案为蓝本的APO方案联合局部放疗可使大细胞“组织细胞”型恶性淋巴瘤患儿获得长期缓解。
